Ionis Pharmaceuticals, Inc. (IONS)

Over the past year, Ionis Pharmaceuticals' stock (IONS) has seen significant movement, with its price rising by 131.62% and trading between a low of $23.95 and a peak of $86.74. Key events impacting the stock in the past six months include FDA approval of Tryngolza in December 2024, positive Phase 3 results for olezarsen and zilganersen in September 2025, Q4 2025 financial results reporting an adjusted net loss per share of $1.14 and total revenue of $203 million, and a Tryngolza repricing in March 2026.

Ionis Pharmaceuticals, Inc. exhibits some demand seasonality, though its consistency score is rated as "Poor" (38.7) over 27 years of data. Historically, August has been the strongest month for IONS, with an average return of 5.76% and a 58% win rate. Conversely, March tends to be the weakest month, averaging a -1.92% return. Another analysis suggests June has the highest probability of a positive return (80.00%), while October has the lowest (20.00%).

Ionis Pharmaceuticals, Inc. (IONS) is a biotechnology company specializing in RNA-targeted medicines, founded in 1989 and headquartered in Carlsbad, California. Ionis operates within the biotechnology sector, focusing on RNA therapeutics, antisense oligonucleotides, RNA interference, and CRISPR-based approaches, with the mission to address unmet medical needs, particularly in rare diseases, neurological disorders, and cardiovascular conditions. Ionis has transitioned into a commercial-stage pharmaceutical company with several approved medicines and a robust pipeline, including Spinraza, Tegsedi, Waylivra, Qalsody, Wainua, Tryngolza, and Dawnzera.

Ionis Pharmaceuticals, Inc. is headquartered in Carlsbad, California, United States. The company's products have received FDA approvals in the U.S. and EMA approvals in Europe, indicating a global market reach, often through strategic partnerships with pharmaceutical companies like Biogen, AstraZeneca, Novartis, GSK, and Roche.

Ionis Pharmaceuticals maintains a strong brand reputation as a pioneer and leader in RNA-targeted therapeutics. Its 35-year history and transition from a research-focused biotech to a commercial-stage company with multiple approved medicines underscore its credibility and innovation in the biotechnology industry. Positive clinical trial results for drugs like olezarsen and zilganersen, leading to significant stock appreciation and anticipated regulatory filings, contribute to a favorable perception within the scientific and investment communities. Analyst ratings generally lean towards "Buy," reflecting confidence in the company's pipeline and commercialization efforts.

Ionis Pharmaceuticals' ownership is primarily distributed among institutional investors, individual shareholders, and company insiders. Institutional investors collectively hold over 94% of Ionis stock as of Q1 2025. Major institutional owners include Fidelity Management & Research Company LLC, The Vanguard Group, Inc., T. Rowe Price Investment Management, Inc., Capital World Investors, BlackRock Institutional Trust Company, N.A., and Wellington Management Group Llp.